3 Grants
2022
Development of SUMO1 small molecule degraders as the first-in-class anticancerdrugs for metastatic colorectal cancer
Bellail, Anita⋅Hao, Chunhai C and Hamdouchi, Chafiq
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 1R44CA265547-01A1), $1,019,583USD, 2022-07-01 -- 2024-06-30
 
Targeting SUMO1 degradation for advanced colon cancer therapy
Bellail, Anita
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 1R01CA266699-01A1), $369,353USD, 2022-07-01 -- 2027-06-30
2018
Development of Small Molecule SUMO1 Inhibitors for Treatment of Glioblastoma
BELLAIL, ANITA
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 1R43CA224461-01A1), $300,000USD, 07/06/2018 -- 06/30/2019